标题:Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1
作者:Huang, Boshi; Kang, Dongwei; Yang, Jiapei; Zhan, Peng; Liu, Xinyong
作者机构:[Huang, Boshi; Kang, Dongwei; Yang, Jiapei; Zhan, Peng; Liu, Xinyong] Shandong Univ, Sch Pharmaceut Sci, Dept Med Chem, Minist Educ,Key Lab Chem Biol, 更多
通讯作者:Zhan, P;Liu, XY
通讯作者地址:[Zhan, P; Liu, XY]Shandong Univ, Sch Pharmaceut Sci, Dept Med Chem, Minist Educ,Key Lab Chem Biol, 44 West Culture Rd, Jinan 250012, Shandong, Peoples 更多
来源:EXPERT OPINION ON THERAPEUTIC PATENTS
出版年:2016
卷:26
期:2
页码:281-289
DOI:10.1517/13543776.2016.1113256
关键词:HIV-1 inhibitors; diarylpyrimidine; Aqueous solubility; diaryltriazine;; NNRTI; drug design
摘要:Diarylpyrimidine and diaryltriazine derivatives, two representative structurally related classes of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with robust potencies against wild-type and several mutant strains of HIV-1, have attracted more and more attention in the last decade. However, they have been suffering from poor aqueous solubility. A series of novel diarylpyrimidines and diaryltriazines with solubilizing substituents attached to the central rings were reported as potent NNRTIs in the patent US20140378443A1. Some compounds exhibited potencies against wild-type HIV-1 which were comparable or even superior to those of dapivirine, etravirine and rilpivirine. In addition, dramatically enhanced solubilities were observed for these new compounds. Moreover, some structure optimization strategies for improving aqueous solubility are detailed in this review, providing new insights into development of next-generation NNRTIs endowed with favorable solubility. We anticipate that application of these strategies will ultimately lead to discovery of new anti-HIV drug candidates.
收录类别:SCOPUS;SCIE
WOS核心被引频次:7
Scopus被引频次:7
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-84957536359&doi=10.1517%2f13543776.2016.1113256&partnerID=40&md5=82a992f25251922788722b93e1356bfc
TOP